Compounds > estradiol-17-stearate
Page last updated: 2024-11-06

estradiol-17-stearate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Estradiol-17-stearate is a synthetic steroid hormone that is a derivative of estradiol. It is an ester of estradiol and stearic acid. Estradiol-17-stearate has been investigated for its potential use in hormone replacement therapy (HRT), as well as for its potential to treat osteoporosis and other conditions. However, its use has been limited due to concerns about its potential side effects. Estradiol-17-stearate is typically synthesized by reacting estradiol with stearic acid in the presence of a catalyst. It is a white, crystalline solid that is insoluble in water but soluble in organic solvents. Estradiol-17-stearate is an agonist of the estrogen receptor, and it has been shown to have a number of pharmacological effects, including promoting bone growth, reducing cholesterol levels, and increasing uterine weight. However, estradiol-17-stearate can also have undesirable side effects, such as nausea, vomiting, breast tenderness, and increased risk of blood clots. Due to its potential for side effects, estradiol-17-stearate is not currently available for clinical use in the United States. However, it is being investigated in clinical trials for its potential to treat a number of conditions, including osteoporosis, endometriosis, and breast cancer. Estradiol-17-stearate is a relatively new compound, and its long-term effects are not fully understood. Further research is needed to determine its safety and efficacy before it can be used for clinical purposes.'

estradiol-17-stearate: RN given refers to (17beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID67100
SCHEMBL ID7751687
MeSH IDM0132021

Synonyms (11)

Synonym
82205-00-3
estradiol-17-stearate
[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] octadecanoate
(3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl) octadecanoate
estra-1,3,5(10)-triene-3,17-diol (17beta)-, 17-octadecanoate
59g2kr8qbg ,
unii-59g2kr8qbg
estradiol 17-o-octadecanoate
SCHEMBL7751687
DTXSID401002548
17beta-estra-1,3,5(10)-triene-3,17-diol 17-octadecanoate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (63.64)18.7374
1990's1 (9.09)18.2507
2000's3 (27.27)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.07 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
corticosterone
[no description available]		1.971011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		1.971017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		1.971017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
raloxifene hydrochloride
Raloxifene Hydrochloride: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.. raloxifene hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.		1.9710hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
estradiol 17-sulfate
[no description available]		1.97103-hydroxy steroid;
phenolic steroid;
steroid sulfate		human urinary metabolite
piperidines
Piperidines: A family of hexahydropyridines.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.420
Cancer of Pituitary
[description not available]		02.0410
Experimental Mammary Neoplasms
[description not available]		02.0410
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.420
Pituitary Neoplasms
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.		02.0410
Hyperplasia
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.		0210
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		0210
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9710
Menopause
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.		01.9710